ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of biologic
therapies for life-threatening, drug-resistant infectious diseases,
today announced that the abstract entitled “PK-PD Relationship and
PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase
(CF-301) in Pre-Clinical Models”, has been selected for an
Outstanding Abstract Award sponsored by the American Society for
Microbiology (ASM) and determined by the ASM Microbe Program
Committee. In addition, ContraFect will present novel data on
exebacase, its lead lysin product candidate and its Gram-negative
lysin discovery program at ASM Microbe 2019, to be held from June
20-24, 2019, in San Francisco.
The Outstanding Abstract Award is dedicated to
highlighting a limited number of outstanding abstracts selected
from eight different areas of focus at ASM Microbe. The abstract
selected for this award details the pharmacokinetic properties of
exebacase with respect to efficacy demonstrated in animal models.
This Outstanding Abstract Award will be bestowed on Saturday, June
22, 2019 at 2:00 p.m. PST in 203/204 South 3.
The company’s presentations include results from
new in vivo and in vitro studies of its lead lysin exebacase and
lysins targeting Gram-negative pathogens. Data will be presented
which demonstrate the activity of exebacase, used in addition to
daptomycin, in several different in vivo models of Staphylococcus
aureus (Staph aureus) infection and in an in vitro endocardial
vegetation model. ContraFect will also present data from its
Gram-negative lysin discovery program demonstrating the
bactericidal effects, synergy with antibiotics, and antibiofilm
effects of its lysins against Pseudomonas aeruginosa (P.
aeruginosa) in human serum.
“We are excited to present additional
preclinical data at ASM Microbe which further underpin our Phase 2
clinical results, where we demonstrated that the addition of
exebacase to standard of care (SOC) antibiotics has the potential
to improve clinical outcomes for patients with Staph aureus
bacteremia, particularly for those with methicillin-resistant Staph
aureus, or MRSA,” said Cara Cassino, M.D., Chief Medical Officer
and Executive Vice President of Research and Development at
ContraFect. “We also look forward to presenting new data on our
lead Gram-negative lysins against P. aeruginosa. These data further
highlight the therapeutic potential of direct lytic agents against
a range of dangerous Gram-negative pathogens.”
Presentation Details:
Presentation
Title: Pharmacodynamic Assessment of
Lysin CF-301 (exebacase) in Addition to Daptomycin against
Staphylococcus aureus in the Neutropenic Murine Thigh Infection
Model Session: AAR07 – Preclinical Antimicrobial
Pharmacokinetics and PharmacodynamicsSession Day &
Time: Friday, June 21, 2019, 10:30 a.m. – 5:00 p.m.
PST Poster Board Number: FRIDAY - AAR-768
Presentation Title: PK-PD
Relationship and PK Driver of Efficacy of the Novel Antibacterial
Lysin Exebacase (CF-301) in Pre-Clinical Models
Session: AAR07 – Preclinical Antimicrobial
Pharmacokinetics and Pharmacodynamics Session Day &
Time: Friday, June 21, 2019, 10:30 a.m. – 5:00 p.m.
PST Poster Board Number: FRIDAY - AAR-775
Presentation
Title: Bacteriophage Lysin CF-301
(Exebacase) in Addition to Daptomycin in a Simulated Endocardial
Vegetation (SEV) PK/PD Model Session: AAR06 –
Novel Approaches: Therapies, Diagnostics and Drug Discovery:
Biologics Session Day & Time: Sunday, June 23,
2019: 10:30 a.m. – 4:00 p.m. PST Poster Board
Number: SUNDAY - AAR-671
Presentation
Title: CF-301 and Daptomycin
Treatment of Methicillin-Resistant Staphylococcus aureus Associated
Experimental Osteomyelitis Session: AAR06 – Novel
Approaches: Therapies, Diagnostics and Drug Discovery: Biologics
Session Day & Time: Sunday, June 23,
2019: 10:30 a.m. – 4:00 p.m. PST Poster Board
Number: SUNDAY - AAR-679
Presentation
Title: Lysins Exhibit Potent
Bactericidal Activity, Synergy and Antibiofilm Effects against
Pseudomonas aeruginosa in Human Serum and Pulmonary Surfactant
Session: AAR07 - To Kill A Biofilm - Novel
Therapeutic ApproachesSession Day &
Time: Sunday, June 23, 2019: 11:00 a.m. – 1:00 p.m.
PSTPoster Board Number: SUNDAY - AAR-695
The abstracts can be accessed through
the ASM Microbe website. Following the meeting, the
presentation posters will be available on the ContraFect
website.
About ContraFect:
ContraFect is a biotechnology company focused on
discovering and developing differentiated biologic therapies for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our platform of direct
lytic agents (DLAs), which include lysins and amurin peptides.
Lysins are a new therapeutic class of DLAs derived from
bacteriophage which are recombinantly produced, antimicrobial
proteins with a novel mechanism of action associated with the rapid
killing of target bacteria, eradication of biofilms and synergy
with conventional antibiotics. We believe that the properties of
our lysins will make them suitable for targeting
antibiotic-resistant organisms, such as Staph aureus and P.
Aeruginosa, which can cause serious infections such as bacteremia,
pneumonia and osteomyelitis. We have clinically completed a Phase 2
clinical trial for the treatment of Staph aureus bacteremia,
including endocarditis with our lead lysin candidate, exebacase
(CF-301) which is the first lysin to enter clinical studies in the
U.S.
About Exebacase (CF-301):
Exebacase (CF-301) is a recombinantly-produced
lysin (cell wall hydrolase enzyme) with potent bactericidal
activity against Staph aureus, a major cause of blood stream
infections (BSIs) also known as bacteremia. Exebacase has the
potential to be a first-in-class treatment for Staph aureus
bacteremia. It has a novel, rapid, and specific mechanism of
bactericidal action against Staph aureus. By targeting a conserved
region of the cell wall that is vital to bacteria, resistance is
less likely to develop to exebacase. In addition, in vitro and in
vivo experiments have shown that exebacase is highly active against
biofilms which complicate Staph aureus infections. Exebacase was
licensed from The Rockefeller University and is being developed at
ContraFect.
Forward-Looking
Statements:
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding the
Company’s ability to discover and develop differentiated
biological therapies for life-threatening, drug-resistant
infectious diseases, whether the data on exebacase and its
Gram-negative lysin discovery program presented at ASM Microbe 2019
is novel, statements made regarding in vivo and in vitro studies,
whether the Phase 2 clinical results demonstrated that the addition
of exebacase to SOC antibiotics has the potential to improve
clinical outcomes for patients with Staph aureus bacteremia,
particularly for those with MRSA, whether the data underpins the
Phase 2 results, whether the data further highlights the
therapeutic potential of direct lytic agents against a range of
dangerous Gram-negative pathogens, information provided regarding
presentations, the Company’s ability to address life threatening
infections using its therapeutic product candidates from its DLA
platform which includes lysins and amurin peptides, whether lysins
are a new therapeutic class of DLAs derived from bacteriophage
which are recombinantly produced, antimicrobial proteins with a
novel mechanism of action associated with the rapid killing of
target bacteria, eradication of biofilms and synergy with
conventional antibiotics, whether the properties of the Company’s
lysins will make them suitable for targeting antibiotic-resistant
organisms, such as Staph aureus and P. aeruginosa, whether
exebacase has the potential to be a first-in-class treatment for
Staph aureus bacteremia and whether exebacase is highly active
against biofilms which complicate Staph aureus infections.
Forward-looking statements are statements that are not historical
facts, nor assurances of future performance. Instead, they are
based on ContraFect’s current beliefs, expectations and assumptions
regarding the future of its business, future plans, strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent risks, uncertainties and
changes in circumstances that are difficult to predict and many of
which are beyond ContraFect’s control, including those detailed in
ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations
Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Lauren StivalStern Investor RelationsTel: 212-362-1200Email:
lauren.stival@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Sep 2023 to Sep 2024